Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis
2019; 39(2): 218-222
Ann Lab Med 2013; 33(2): 97-104
Published online March 1, 2013 https://doi.org/10.3343/alm.2013.33.2.97
Copyright © Korean Society for Laboratory Medicine.
Hee Jae Huh, M.D.1, Soo Hyun Lee, M.D.2, Keon Hee Yoo, M.D.2, Ki Woong Sung, M.D.2, Hong Hoe Koo, M.D.2, Kihyun Kim, M.D.3, Jun-Ho Jang, M.D.3, Chulwon Jung, M.D.3, Sun-Hee Kim, M.D.1, and Hee-Jin Kim, M.D.1
Departments of Laboratory Medicine & Genetics1, Pediatrics2, and Medicine3, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Hee-Jin Kim
Department of Laboratory Medicines & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Therapy-related myeloid neoplasms (t-MN) occur as late complications of cytotoxic therapy. This study reviewed clinical and cytogenetic characteristics of patients with t-MN at a single institution in Korea. Methods: The study subjects included 39 consecutive patients diagnosed with t-MN. Each subject’s clinical history of previous diseases, treatments, and laboratory data was reviewed, including cytogenetics. The primary diagnosis was hematologic malignancy in 14 patients and solid tumor in 25 patients. Results: Therapy-related acute myeloid leukemia (t-AML, 66.7%) was found to be more common than therapy-related myelodysplastic syndrome (t-MDS). Primary hematologic malignancies that were commonly implicated included mature B-cell neoplasm and acute leukemia. Breast cancer was the most common primary solid tumor. The mean time interval from cytotoxic therapy initiation to t-MN detection was 49 months. Chromosomal aberrations were observed in 35 patients, and loss of chromosome 5, 7, or both accounted for 41% of all cases. Balanced rearrangements occurred in 13 patients; these patients showed shorter latency intervals (mean, 38 months) than patients with loss of chromosome 5 or 7 (mean, 61 months). Conclusions: In this study, we determined the clinical and cytogenetic characteristics of Korean patients with t-MN. Although our results were generally consistent with those of previous reports, we found that t-MN resulting from de novo leukemia was common and that t-AML was more common than t-MDS at presentation. Multi-institutional studies involving a larger number of patients and additional parameters are required to investigate the epidemiology, genetic predisposition, and survival rate of t-MN in Korea.
Keywords: Therapy-related neoplasms, Myelodysplastic syndrome, Acute myeloid leukemia, Cytogenetics, Korea